Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Amortization of Deferred Charges (2019 - 2025)

Amphastar Pharmaceuticals has reported Amortization of Deferred Charges over the past 7 years, most recently at $866000.0 for Q4 2025.

  • Quarterly results put Amortization of Deferred Charges at $866000.0 for Q4 2025, up 19.61% from a year ago — trailing twelve months through Dec 2025 was $2.6 million (down 31.78% YoY), and the annual figure for FY2025 was $3.4 million, down 44.38%.
  • Amortization of Deferred Charges for Q4 2025 was $866000.0 at Amphastar Pharmaceuticals, up from $500000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for AMPH hit a ceiling of $5.2 million in Q3 2023 and a floor of -$2.3 million in Q4 2021.
  • Median Amortization of Deferred Charges over the past 5 years was $724000.0 (2024), compared with a mean of $962210.5.
  • Biggest five-year swings in Amortization of Deferred Charges: crashed 334.58% in 2021 and later surged 9610.0% in 2023.
  • Amphastar Pharmaceuticals' Amortization of Deferred Charges stood at -$2.3 million in 2021, then surged by 101.33% to $30000.0 in 2022, then surged by 9610.0% to $2.9 million in 2023, then crashed by 75.15% to $724000.0 in 2024, then grew by 19.61% to $866000.0 in 2025.
  • The last three reported values for Amortization of Deferred Charges were $866000.0 (Q4 2025), $500000.0 (Q3 2025), and $500000.0 (Q2 2025) per Business Quant data.